F14 - Psychedelics: State of the Union

Tuesday, April 28, 2026

4:00 PM - 5:00 PM MDT

Location: 205

The field of psychedelic-assisted therapy is moving fast. This forward-looking panel will take stock of where the field stands today and what to expect in the year ahead, covering the latest on FDA approval timelines and the drug pipeline; the workforce, reimbursement, and operational challenges that will shape clinical access post-approval; and policy priorities that advocates are pushing at the state and federal levels. Attendees will leave with a firm grounding in the state of the field and an understanding of how the next twelve months may play out as psychedelics move from clinical trials to possible FDA approval and clinical practice.

Learning Objectives:

Identify psychedelic compounds in late-stage clincial trials and the indications they are being studied to treat.
Naviagate the federal and state policy landscapes as they pertain to psychedelic therapy and psychedelic research.
Identify challenges for integrating psychedelic therapy into clinical practice and potential solutions.

Disclosure(s):

Jazz Glastra, MS: No financial relationships to disclose

Leith States, MD, MPH, MBA, FACPM: No financial relationships to disclose

Josh Hardman, BSc: No financial relationships to disclose

Breakout Presenter(s)

Jazz Glastra, MS

Senior Director
BrainFutures
Gambier, Ohio

Disclosure(s): No financial relationships to disclose
Leith States, MD, MPH, MBA, FACPM

SVP, Strategic Military Initiatives
Sunstone Therapies
Stafford, Virginia

Disclosure(s): No financial relationships to disclose
Josh Hardman, BSc

Founder & Editor
Psychedelic Alpha
Harrogate, England, United Kingdom

Disclosure(s): No financial relationships to disclose